SCHEMBL16484167

SCHEMBL16484167

COCCn1ccc2nc(Cl)nc(Cl)c21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.36
CASR P41180 6/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
TLR7 Q9NYK1 3/20 0.34
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 2/20 0.32
RAB9A P51151 2/20 0.32
MPO P05164 1/20 0.31
CNR2 P34972 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31
TUBB2A Q13885 1/20 0.31
TUBB8 Q3ZCM7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20261964 0.93 TLR7 (0.35) GRIN2BCASRKMT2ATLR7MAPT
SCHEMBL16386429 0.85 TLR7 (0.45) GRIN2BCASRTLR7
SCHEMBL19661033 0.84 GRM2 (0.35) TLR7TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL20996056 0.81 EGFR (0.33) KMT2AHPGD
SCHEMBL18359327 0.80 CYP19A1 (0.33) TLR7
SCHEMBL29101651 0.79 GLA (0.32)
SCHEMBL3506358 0.78 FGFR1 (0.39) GRIN2BKMT2AMEN1MAPTHPGD
SCHEMBL19661102 0.78 NUDT1 (0.35) TLR7
SCHEMBL15600306 0.77 HDAC1 (0.42) MAPTCNR2
SCHEMBL20996061 0.77 MAPT (0.41) MAPTCNR2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11220504-B2 Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases Janssen Sciences Ireland Unlimited Company (IE) 2022-01-11 US disclosed
US-20190330217-A1 PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES Janssen Sciences Ireland Unlimited Company (IE) 2019-10-31 US disclosed
US-10259814-B2 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN SCIENCES IRELAND UC (IE) 2019-04-16 US disclosed
EP-2906563-B1 PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES JANSSEN SCIENCES IRELAND UC (IE) 2018-02-28 EP disclosed
US-20170044169-A1 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN SCIENCES IRELAND UC (IE) 2017-02-16 US disclosed
US-20170044169-A1 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN SCIENCES IRELAND UC (IE) 2017-02-16 US disclosed
US-9499549-B2 Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN SCIENCES IRELAND UC (IE) 2016-11-22 US disclosed
US-9499549-B2 Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN SCIENCES IRELAND UC (IE) 2016-11-22 US disclosed
US-20150239892-A1 Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN R&D IRELAND (IE) 2015-08-27 US disclosed
US-20150239892-A1 Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases JANSSEN R&D IRELAND (IE) 2015-08-27 US disclosed
WO-2014056953-A1 PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES JANSSEN R&D IRELAND (IE) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11220504-B2 Pyrrolo[3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases TYMS, TYMP, DPYD GRIN2B 3233/4885CASR 4175/4885KMT2A 2677/4885
US-20150239892-A1 Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases TYMS, TYMP, DPYD GRIN2B 3025/4885CASR 4131/4885KMT2A 2719/4885
US-20170044169-A1 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases TYMS, TYMP, DPYD GRIN2B 3233/4885CASR 4175/4885KMT2A 2677/4885
US-10259814-B2 Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases TYMS, TYMP, DPYD GRIN2B 3233/4885CASR 4175/4885KMT2A 2677/4885
US-20190330217-A1 PYRROLO[3,2-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES TYMS, TYMP, DPYD GRIN2B 3233/4885CASR 4175/4885KMT2A 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.